533 related articles for article (PubMed ID: 33124941)
1. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.
Sriram K; Insel PA
Physiol Rev; 2021 Apr; 101(2):545-567. PubMed ID: 33124941
[TBL] [Abstract][Full Text] [Related]
2. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship.
D'Ardes D; Boccatonda A; Cocco G; Fabiani S; Rossi I; Bucci M; Guagnano MT; Schiavone C; Cipollone F
World J Gastroenterol; 2022 Mar; 28(11):1102-1112. PubMed ID: 35431501
[TBL] [Abstract][Full Text] [Related]
3. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses.
Nascimento Conde J; Schutt WR; Gorbunova EE; Mackow ER
mBio; 2020 Dec; 11(6):. PubMed ID: 33310781
[TBL] [Abstract][Full Text] [Related]
4. Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Gando S; Wada T
Front Immunol; 2021; 12():649122. PubMed ID: 34177896
[TBL] [Abstract][Full Text] [Related]
5. Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.
Díaz-García E; García-Tovar S; Alfaro E; Zamarrón E; Mangas A; Galera R; Ruíz-Hernández JJ; Solé-Violán J; Rodríguez-Gallego C; Van-Den-Rym A; Pérez-de-Diego R; Nanwani-Nanwani K; López-Collazo E; García-Rio F; Cubillos-Zapata C
Front Immunol; 2022; 13():847894. PubMed ID: 35173744
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.
Higashikuni Y; Liu W; Obana T; Sata M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769508
[TBL] [Abstract][Full Text] [Related]
7. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
[TBL] [Abstract][Full Text] [Related]
8. Possible role of purinergic signaling in COVID-19.
Franciosi MLM; Lima MDM; Schetinger MRC; Cardoso AM
Mol Cell Biochem; 2021 Aug; 476(8):2891-2898. PubMed ID: 33740184
[TBL] [Abstract][Full Text] [Related]
9. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Verdecchia P; Cavallini C; Spanevello A; Angeli F
Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612
[TBL] [Abstract][Full Text] [Related]
10. Thrombin and protease-activated receptors (PARs) in atherothrombosis.
Martorell L; Martínez-González J; Rodríguez C; Gentile M; Calvayrac O; Badimon L
Thromb Haemost; 2008 Feb; 99(2):305-15. PubMed ID: 18278179
[TBL] [Abstract][Full Text] [Related]
11. Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2.
Dos Anjos F; Simões JLB; Assmann CE; Carvalho FB; Bagatini MD
J Immunol Res; 2020; 2020():8632048. PubMed ID: 33299899
[TBL] [Abstract][Full Text] [Related]
12. The role of platelets, neutrophils and endothelium in COVID-19 infection.
Falcinelli E; Petito E; Gresele P
Expert Rev Hematol; 2022 Aug; 15(8):727-745. PubMed ID: 35930267
[TBL] [Abstract][Full Text] [Related]
13. Thromboinflammation in coronavirus disease 2019: The clot thickens.
Iffah R; Gavins FNE
Br J Pharmacol; 2022 May; 179(10):2100-2107. PubMed ID: 34128218
[TBL] [Abstract][Full Text] [Related]
14. Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.
Shafaghat Z; Ghomi AK; Khorramdelazad H; Safari E
Inflammopharmacology; 2023 Dec; 31(6):3005-3020. PubMed ID: 37805959
[TBL] [Abstract][Full Text] [Related]
15. Linking ACE2 and angiotensin II to pulmonary immunovascular dysregulation in SARS-CoV-2 infection.
Seltzer S
Int J Infect Dis; 2020 Dec; 101():42-45. PubMed ID: 32950735
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis in COVID-19: Impact on Clot Lysis and Modulation of Inflammation.
Sugimoto MA; Perucci LO; Tavares LP; Teixeira MM; Sousa LP
Curr Drug Targets; 2022; 23(17):1578-1592. PubMed ID: 36221881
[TBL] [Abstract][Full Text] [Related]
17. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.
Divani AA; Andalib S; Di Napoli M; Lattanzi S; Hussain MS; Biller J; McCullough LD; Azarpazhooh MR; Seletska A; Mayer SA; Torbey M
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104941. PubMed ID: 32689643
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.
Chang JC
Vasc Health Risk Manag; 2021; 17():273-298. PubMed ID: 34103921
[TBL] [Abstract][Full Text] [Related]
19. Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19.
Hottz ED; Martins-Gonçalves R; Palhinha L; Azevedo-Quintanilha IG; de Campos MM; Sacramento CQ; Temerozo JR; Soares VC; Dias SSG; Teixeira L; Castro Í; Righy C; Souza TML; Kurtz P; Andrade BB; Nakaya HI; Monteiro RQ; Bozza FA; Bozza PT
Blood Adv; 2022 Sep; 6(17):5085-5099. PubMed ID: 35420680
[TBL] [Abstract][Full Text] [Related]
20. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy.
Zhang J; Tecson KM; McCullough PA
Rev Cardiovasc Med; 2020 Sep; 21(3):315-319. PubMed ID: 33070537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
